ABSTRACT
Metastatic renal cell cancer has been one of the malignancies in focus for therapeutic attempts with such in vitro expanded tumor infiltrating lymphocytes (TIL). This chapter discusses a monoclonal antibody and device-based technology, developed by Applied Immune Sciences, has been used to capture CD8+ subpopulations present in renal cell carcinoma-derived TIL. Renal cell carcinoma samples were obtained from resected kidneys post-surgery after obtaining patient informed consent. Cells from bulk-cultured TIL were concentrated, and each device was loaded with the concentrated bulk cultured TIL. The non-adherent fraction was removed and the capture surface rinsed leaving the desired cells on the surface. The first phase of TIL production involved lymphocyte cultivation from whole tumor digest. Initial lymphocyte composition was highly variable, ranging from 27% to 70% immediately post-digestion. A significant correlation was also found between the antitumor cytotoxicity and the number of days that the CD8+ TIL culture was propagated ex vivo.
